4006-776-356 出国就医服务电话

免费获得国外相关药品，最快 1 个工作日回馈药物信息

出境医 / 临床实验 / ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Study Description
Brief Summary:
This phase Ib/II trial studies the side effects and best dose of FT-2102 when given together with ASTX727 in treating patients with IDH1-mutated myelodysplastic syndrome or acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). ASTX727 is an oral deoxyribonucleic acid (DNA) methyltransferase (DNMT) inhibitor. DNA methylation is necessary for cell differentiation and development. Changes to the methylation profile can lead to DNA instability which can cause diseases like cancer. DNMT inhibitors target and inhibit these changes. FT-2102 is an isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 is a type of protein involved in metabolism, or the process of providing the body's cells with energy. FT-2102 may stop the abnormal IDH1 protein and may reduce 2-HG levels in diseased cells to levels found in normal cells. Giving ASTX727 and FT-2102 may work better in treating patients with myelodysplastic syndrome or acute myeloid leukemia compared to ASTX727 and FT-2102 alone.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Myelodysplastic Syndrome Drug: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727 Drug: IDH-1 Inhibitor FT-2102 Phase 1 Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

  • To evaluate the safety of IDH-1 inhibitor FT-2102 (FT-2102) in combination with CDA inhibitor E7727/decitabine combination agent ASTX727 (ASTX727) in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients with IDH1 R132 mutations. (Phase Ib)
  • To evaluate the response rate (overall response rate [ORR], complete response [CR], complete remission with partial hematologic recovery (CRh), complete remission with incomplete blood count recovery [CRi], morphologic leukemia-free state [MLFS], partial response [PR]) of the combination of ASTX727 and the IDH1-inhibitor, FT-2102 in subjects with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with IDH1 R132 mutations. (Phase II)

SECONDARY OBJECTIVES:

  • To confirm the phase II recommended dosing level of FT-2102 and ASTX727 in combination. (Phase Ib)
  • To determine the pharmacokinetics of FT-2102 and ASTX727 in combination. (Phase Ib)
  • To determine the reduction of bone marrow blasts. (Phase II)
  • To determine the overall survival and event-free survival. (Phase II)
  • To determine the levels of 2-HG in the blood and blood cells after treatment. (Phase II)
  • To determine the relationship of 2-HG reduction to clinical response. (Phase II)

OUTLINE: This is a phase Ib, dose-escalation of IDH-1 inhibitor FT-2102 followed by a phase II study.

Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 orally (PO) once daily (QD) on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 3 months for 12 months, and then periodically for up to 5 years.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IB/II Study to Evaluate the Safety, Tolerability, and Efficacy of ASTX727 and FT-2102 in IDH1-Mutated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Actual Study Start Date : August 27, 2019
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2022
Arms and Interventions
Arm Intervention/treatment
Experimental: Treatment (ASTX727, FT-2102)
Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 PO QD on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
 Drug: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
Given by mouth
Other Name: ASTX727

Drug: IDH-1 Inhibitor FT-2102
Given by mouth
Other Name: FT 2102, FT-2102, IDH1-R132 Inhibitor FT-2102
Outcome Measures
Primary Outcome Measures :
  1. Incidence of adverse events (Phase Ib) [ Time Frame: Up to 30 days ]
    Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

  2. Response rate (Phase II) [ Time Frame: Approximately 12 months ]
    calculated for each cohort, together with 95% confidence intervals based on exact binomial distributions.


Secondary Outcome Measures :
  1. To confirm the phase II recommended dosing level (1b) [ Time Frame: At 28 days ]
  2. Pharmacokinetics parameters (1b) [ Time Frame: Approximately 12 months ]
    analysis of plasma concentrations during the dose escalation phase of the study

  3. Reduction of bone marrow blasts (phase II) [ Time Frame: Approximately 12 months ]
  4. Overall survival (Phase II) [ Time Frame: Up to 2 years ]
    Time from randomization to death due to any cause

  5. Event-Free Survival (Phase II) [ Time Frame: Up to 2 years ]
    Time from start of treatment to event that treatment was intended to prevent or delay

  6. Measure change in levels of 2-HG in the blood and blood cells after treatment (Phase II) [ Time Frame: Up to 12 months ]
  7. Compare 2-HG change to clinical response (Phase II) [ Time Frame: Up to 12 months ]

Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must voluntarily sign an informed consent document (ICF)
  • Morphologically confirmed diagnosis of MDS (inclusive of MDS/MPN) or AML in accordance with World Health Organization (WHO) diagnostic criteria

  • Phase Ib: Subjects may have

    • Relapsed/refractory AML or MDS or
    • Treatment naive AML

  • Phase II Expansion: Subjects may have

    • Relapsed/refractory AML or MDS or
    • Treatment naive AML or
    • Treatment naive MDS
  • For patients with MDS, must have a Revised International Prognostics Scoring System (IPSS-R) risk category of intermediate, high, or very high
  • Confirmed IDH1 R132 mutation
  • A bone marrow biopsy must be performed and tissue collected for entrance to the trial
  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Life expectancy of at least 3 months in the assessment of the investigator
  • Recovery from the non-hematologic toxic effects of prior treatment to grade =< 1, or baseline value according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03 classification (excluding infertility, alopecia, or grade 1 neuropathy)
  • Must have adequate hepatic and renal function as demonstrated by the following:

ALT (SGPT) and/or AST (SGOT) ≤ 3x upper limit of normal (ULN); Direct bilirubin ≤ 1.5 x ULN(or ≤ 2x ULN if due to Gilbert's disease); Serum creatinine of 1.5 x ULN or creatinine clearance of > 50 mL/min (whichever is lower)

  • Baseline Fridericia's correction formula (QTcF) =< 450 msec (average of the QTcF values of screening triplicate electrocardiography [ECG]swith approximately two-minute intervals ) except for those patients with a bundle branch block (BBB)
  • For fertile men and women, agreement to use effective contraceptive methods for the duration of study participation and 90 days after the last dose of study medication

Exclusion Criteria:

  • Treatment naive patients who are suitable for and willing to receive intensive induction chemotherapy
  • Patients with active, uncontrolled infection. Patients with infection under active treatment and controlled with antibiotics are eligible
  • Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol
  • Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal liver function test [LFT]s and undetectable viral loads are allowed)
  • Women who are pregnant or nursing
  • Organ transplant recipients other than bone marrow transplant
  • Autologous hematologic stem cell transplant within 3 months of study entry. Allogeneic hematologic stem cell transplant within 6 months. Grade II, or greater, active graft-versus- host disease
  • Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of FT-2102/ASTX727. For investigational drugs for which 5 half-lives is less than 21 days, a minimum of 10 days between termination of the investigational drug and administration of FT-2102/ASTX727 is required
  • Any major surgery, chemotherapy, or immunotherapy within the last 21 days (limited palliative radiation is allowed >= 2 weeks); concurrent hydroxyurea is allowed if less than or equal to 2 grams daily
  • Ongoing immunosuppressive therapy including systemic corticosteroids (prednisone or equivalent =< 20 mg daily allowed as clinically warranted). Patients are allowed to use topical or inhaled corticosteroids
  • Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol.
  • Patients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g., malabsorption, resection, etc.) deemed by the Investigator to jeopardize intestinal absorption
  • Patients receiving intrathecal chemotherapy for active central nervous system (CNS) disease
  • Patients who have exhibited allergic reactions to a previously administered IDH1 inhibitor
  • Patients with acute promyelocytic leukemia (APL)
Contacts and Locations

Sponsors and Collaborators
Vanderbilt-Ingram Cancer Center
Astex Pharmaceuticals, Inc.
Forma Therapeutics, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Paul Ferrell, MD Vanderbilt Medical Center
Tracking Information
First Submitted Date  ICMJE July 5, 2019
First Posted Date  ICMJE July 10, 2019
Last Update Posted Date July 7, 2020
Actual Study Start Date  ICMJE August 27, 2019
Estimated Primary Completion Date March 31, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 5, 2019)
  • Incidence of adverse events (Phase Ib) [ Time Frame: Up to 30 days ]
    Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
  • Response rate (Phase II) [ Time Frame: Approximately 12 months ]
    calculated for each cohort, together with 95% confidence intervals based on exact binomial distributions.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 28, 2019)
  • To confirm the phase II recommended dosing level (1b) [ Time Frame: At 28 days ]
  • Pharmacokinetics parameters (1b) [ Time Frame: Approximately 12 months ]
    analysis of plasma concentrations during the dose escalation phase of the study
  • Reduction of bone marrow blasts (phase II) [ Time Frame: Approximately 12 months ]
  • Overall survival (Phase II) [ Time Frame: Up to 2 years ]
    Time from randomization to death due to any cause
  • Event-Free Survival (Phase II) [ Time Frame: Up to 2 years ]
    Time from start of treatment to event that treatment was intended to prevent or delay
  • Measure change in levels of 2-HG in the blood and blood cells after treatment (Phase II) [ Time Frame: Up to 12 months ]
  • Compare 2-HG change to clinical response (Phase II) [ Time Frame: Up to 12 months ]
Original Secondary Outcome Measures  ICMJE
 (submitted: July 5, 2019)
  • To confirm the phase II recommended dosing level (1b) [ Time Frame: At 28 days ]
  • Pharmacokinetics parameters (1b) [ Time Frame: Approximately 12 months ]
    analysis of plasma concentrations during the dose escalation phase of the study
  • Reduction of bone marrow blasts (phase II) [ Time Frame: Approximately 12 months ]
  • Overall survival (Phase II) [ Time Frame: Up to 2 years ]
    Time from randomization to death due to any cause
  • Event-Free Survival (Phase II) [ Time Frame: Up to 2 years ]
    Time from start of treatment to event that treatment was intended to prevent or delay
  • Measure reduction in levels of 2-HG in the blood and blood cells after treatment (Phase II) [ Time Frame: Up to 12 months ]
  • Compare 2-HG reduction to clinical response (Phase II) [ Time Frame: Up to 12 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Official Title  ICMJE A Phase IB/II Study to Evaluate the Safety, Tolerability, and Efficacy of ASTX727 and FT-2102 in IDH1-Mutated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Brief Summary This phase Ib/II trial studies the side effects and best dose of FT-2102 when given together with ASTX727 in treating patients with IDH1-mutated myelodysplastic syndrome or acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). ASTX727 is an oral deoxyribonucleic acid (DNA) methyltransferase (DNMT) inhibitor. DNA methylation is necessary for cell differentiation and development. Changes to the methylation profile can lead to DNA instability which can cause diseases like cancer. DNMT inhibitors target and inhibit these changes. FT-2102 is an isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 is a type of protein involved in metabolism, or the process of providing the body's cells with energy. FT-2102 may stop the abnormal IDH1 protein and may reduce 2-HG levels in diseased cells to levels found in normal cells. Giving ASTX727 and FT-2102 may work better in treating patients with myelodysplastic syndrome or acute myeloid leukemia compared to ASTX727 and FT-2102 alone.
Detailed Description

PRIMARY OBJECTIVES:

  • To evaluate the safety of IDH-1 inhibitor FT-2102 (FT-2102) in combination with CDA inhibitor E7727/decitabine combination agent ASTX727 (ASTX727) in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients with IDH1 R132 mutations. (Phase Ib)
  • To evaluate the response rate (overall response rate [ORR], complete response [CR], complete remission with partial hematologic recovery (CRh), complete remission with incomplete blood count recovery [CRi], morphologic leukemia-free state [MLFS], partial response [PR]) of the combination of ASTX727 and the IDH1-inhibitor, FT-2102 in subjects with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with IDH1 R132 mutations. (Phase II)

SECONDARY OBJECTIVES:

  • To confirm the phase II recommended dosing level of FT-2102 and ASTX727 in combination. (Phase Ib)
  • To determine the pharmacokinetics of FT-2102 and ASTX727 in combination. (Phase Ib)
  • To determine the reduction of bone marrow blasts. (Phase II)
  • To determine the overall survival and event-free survival. (Phase II)
  • To determine the levels of 2-HG in the blood and blood cells after treatment. (Phase II)
  • To determine the relationship of 2-HG reduction to clinical response. (Phase II)

OUTLINE: This is a phase Ib, dose-escalation of IDH-1 inhibitor FT-2102 followed by a phase II study.

Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 orally (PO) once daily (QD) on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 3 months for 12 months, and then periodically for up to 5 years.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Recurrent Acute Myeloid Leukemia
  • Recurrent Myelodysplastic Syndrome
  • Refractory Acute Myeloid Leukemia
  • Refractory Myelodysplastic Syndrome
Intervention  ICMJE
  • Drug: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
    Given by mouth
    Other Name: ASTX727
  • Drug: IDH-1 Inhibitor FT-2102
    Given by mouth
    Other Name: FT 2102, FT-2102, IDH1-R132 Inhibitor FT-2102
Study Arms  ICMJE Experimental: Treatment (ASTX727, FT-2102)
Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 PO QD on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Drug: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
  • Drug: IDH-1 Inhibitor FT-2102
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: July 1, 2020) 		0
Original Estimated Enrollment  ICMJE
 (submitted: July 5, 2019) 		80
Estimated Study Completion Date  ICMJE March 31, 2022
Estimated Primary Completion Date March 31, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Must voluntarily sign an informed consent document (ICF)
  • Morphologically confirmed diagnosis of MDS (inclusive of MDS/MPN) or AML in accordance with World Health Organization (WHO) diagnostic criteria

  • Phase Ib: Subjects may have

    • Relapsed/refractory AML or MDS or
    • Treatment naive AML

  • Phase II Expansion: Subjects may have

    • Relapsed/refractory AML or MDS or
    • Treatment naive AML or
    • Treatment naive MDS
  • For patients with MDS, must have a Revised International Prognostics Scoring System (IPSS-R) risk category of intermediate, high, or very high
  • Confirmed IDH1 R132 mutation
  • A bone marrow biopsy must be performed and tissue collected for entrance to the trial
  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Life expectancy of at least 3 months in the assessment of the investigator
  • Recovery from the non-hematologic toxic effects of prior treatment to grade =< 1, or baseline value according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03 classification (excluding infertility, alopecia, or grade 1 neuropathy)
  • Must have adequate hepatic and renal function as demonstrated by the following:

ALT (SGPT) and/or AST (SGOT) ≤ 3x upper limit of normal (ULN); Direct bilirubin ≤ 1.5 x ULN(or ≤ 2x ULN if due to Gilbert's disease); Serum creatinine of 1.5 x ULN or creatinine clearance of > 50 mL/min (whichever is lower)

  • Baseline Fridericia's correction formula (QTcF) =< 450 msec (average of the QTcF values of screening triplicate electrocardiography [ECG]swith approximately two-minute intervals ) except for those patients with a bundle branch block (BBB)
  • For fertile men and women, agreement to use effective contraceptive methods for the duration of study participation and 90 days after the last dose of study medication

Exclusion Criteria:

  • Treatment naive patients who are suitable for and willing to receive intensive induction chemotherapy
  • Patients with active, uncontrolled infection. Patients with infection under active treatment and controlled with antibiotics are eligible
  • Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol
  • Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal liver function test [LFT]s and undetectable viral loads are allowed)
  • Women who are pregnant or nursing
  • Organ transplant recipients other than bone marrow transplant
  • Autologous hematologic stem cell transplant within 3 months of study entry. Allogeneic hematologic stem cell transplant within 6 months. Grade II, or greater, active graft-versus- host disease
  • Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of FT-2102/ASTX727. For investigational drugs for which 5 half-lives is less than 21 days, a minimum of 10 days between termination of the investigational drug and administration of FT-2102/ASTX727 is required
  • Any major surgery, chemotherapy, or immunotherapy within the last 21 days (limited palliative radiation is allowed >= 2 weeks); concurrent hydroxyurea is allowed if less than or equal to 2 grams daily
  • Ongoing immunosuppressive therapy including systemic corticosteroids (prednisone or equivalent =< 20 mg daily allowed as clinically warranted). Patients are allowed to use topical or inhaled corticosteroids
  • Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol.
  • Patients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g., malabsorption, resection, etc.) deemed by the Investigator to jeopardize intestinal absorption
  • Patients receiving intrathecal chemotherapy for active central nervous system (CNS) disease
  • Patients who have exhibited allergic reactions to a previously administered IDH1 inhibitor
  • Patients with acute promyelocytic leukemia (APL)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT04013880
Other Study ID Numbers  ICMJE VICC HEM 18165
NCI-2019-04103 ( Registry Identifier: NCI, Clinical Trials Reporting Program )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Paul Ferrell, Vanderbilt-Ingram Cancer Center
Study Sponsor  ICMJE Vanderbilt-Ingram Cancer Center
Collaborators  ICMJE
  • Astex Pharmaceuticals, Inc.
  • Forma Therapeutics, Inc.
Investigators  ICMJE
Principal Investigator: Paul Ferrell, MD Vanderbilt Medical Center
PRS Account Vanderbilt-Ingram Cancer Center
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

治疗医院

新药特效药

治疗案例

前沿医讯